SynKinase

BLZ-945

As low as CHF 0.00
In stock
Only %1 left
SYN-1197-M0011 mgCHF 227.00
SYN-1197-M0055 mgCHF 497.00
SYN-1197-M01010 mgCHF 780.00
SYN-1197-M05050 mgINQ
SYN-1197-M100100 mgINQ
 

Specifications / Handling

More Information
Product Details
Synonyms BLZ945
Product Type Chemical
Properties
Formula C20H22N4O3S
MW 398.5
CAS 953769-46-5
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by SynKinase.
Other Product Data Target: c-FMS | Kinase Group: PTK | Substrate: Tyrosine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key ADZBMFGQQWPHMJ-RHSMWYFYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
Safety Data Sheet Download PDF Download PDF
Product Specification Sheet
Datasheet Download PDF Download PDF

Scientific Background Information

Product Description
BLZ945 is an orally active, potent and selective colony stimulating factor 1 receptor (CSF-1R) inhibitor, which inhibits CSF-1R activity with an IC(50) of 1nM and is more than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and Platelet-derived Growth Factor Receptor β (PDGFRβ ) as well as more than 200 additional kinases, confirming the selectivity of the compound.
Product-specific References
  1. Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics: T. Wang, et al.; Int. J. Toxicol. 30, 300 (2011)
  2. CSF-1R inhibition alters macrophage polarization and blocks glioma progression: S.M. Pyonteck, et al.; Nat. Med. 19, 1264 (2013)
  3. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells: D.C. Strachan, et al.; Oncoimmunology 2, e26968 (2013)
  4. Therapeutically reeducating macrophages to treat GBM: C. Garris & M.J. Pittet; Nat. Med. 19, 1207 (2013)
  5. Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite: J.A. Krauser, et al.; Xenobiotica 45, 107 (2015)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.